DYAI Earnings

DYAI reported its earnings on 2026-05-13, showcasing a revenue of 1.11M against an estimate of 5.00M, resulting in a -77.78% surprise. The EPS was -0.05, surpassing the expected 0 by 0%. The stock experienced a -2.89% price change on the earnings day and a 1.48% change over the next five days, reflecting market reactions to the results.

Following DYAI's earnings announcement on 2026-05-13, the stock price moved by -2.89% on the day of the release. Over the subsequent five days, it saw a 1.48% change. Historically, DYAI's stock price tends to shift by an average of 6.79% in the 10 days leading up to earnings and 7.36% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate DYAI's annual revenue to reach 1.53M, while the EPS is projected at -0.04. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between DYAI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, DYAI's stock price typically moves by 6.79% in the 10 days before its earnings and 7.36% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of -0.04 and revenue of 1.53M.

The company reported improved financial metrics, including a reduction in net loss and operating losses, along with a strong cash position. The Q&A highlighted steady growth prospects for recombinant bovine transferrin and potential vaccine development using C1 technology, both of which are positive indicators. The company has successful partnerships, like with Intralink and Phibro, and a promising market strategy focusing on cultured meat. Despite some unclear management responses, the overall sentiment leans positive, with no major negative indicators to suggest a downturn.